Which Is the Appropriate Adjuvant Endocrine Therapy for Premenopausal Patients With Breast Cancer?
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy
Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy
Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer
Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2− Breast Cancer
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer
Socioeconomic and Racial Disparities in the Selection of Chest Wall Boost Radiation Therapy in Californian Women After Mastectomy
Extent of Margin Involvement, Lymphovascular Invasion, and Extensive Intraductal Component Predict for Residual Disease After Wide Local Excision for Breast Cancer
Clinical Implications of Growth Pattern and Extension of Tumor-Associated Intraductal Carcinoma of the Breast
Magnetic Resonance Imaging-Guided Core Needle Breast Biopsies Resulting in High-Risk Histopathologic Findings: Upstage Frequency and Lesion Characteristics